Aktuelle smitsomme sygdomme
Søgeord (zika) valgt.
6 emner vises.
1
Communicable disease threats report, 21-27 January 2024, week 4
ECDC
ECDC Communicable Disease Threats Report, 27.01.2024
Tilføjet 27.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
Læs mere
2
Communicable disease threats report, 21-27 January 2024, week 4
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
Læs mere
3
Notes from the Field: Autism Spectrum Disorder Among Children with Laboratory Evidence of Prenatal Zika Virus Exposure - Puerto Rico, 2023
Morbidity and Mortality Weekly Report (MMWR), 21.07.2023
Tilføjet 21.07.2023
This report describes autism spectrum disorder diagnoses among children with possible prenatal Zika virus exposure.
Læs mere
4
PRO/AH/EDR> Invasive mosquito - Switzerland: (VD)
ProMED, 29.05.2023
Tilføjet 29.05.2023
-- SwitzerlandA native of the tropical and subtropical areas of Southeast Asia, the tiger mosquito typically flies and feeds in the daytime in addition to at dusk and dawn. It has the potential to transmit numerous viruses including the yellow fever virus, dengue fever, and chikungunya fever. It is also capable of hosting and spreading the Zika virus.The tiger mosquito, named after its striped appearance, has spread from its home to many countries through the transport of goods and international
Læs mere
5
Climate Change May Promote the Global Spread of Arboviruses
Medscape Infectious Diseases, 29.04.2023
Tilføjet 29.04.2023
Arboviruses such as chikungunya, dengue, and Zika are being detected in new regions that are ill prepared to confront them. Medscape Medical News
Læs mere
6
PRO/AH/EDR> Zika virus (02): Americas, Europe, research, observations
ProMED, 15.03.2023
Tilføjet 15.03.2023
Zika virus -- Abstract---------BackgroundWe report 2-year persistence of immune response to Takeda's prophylactic purified formalin-inactivated whole Zika virus vaccine candidate (TAK-426) compared with that observed after natural infection.MethodsA randomized, observer-blind, placebo-controlled, dose-selection, phase 1 trial was conducted in 18-49-year-old adults at 9 centers (7 in the United States, 2 in Puerto Rico) from 13 Nov 2017 to 24 Nov 2020. Primary objectives were safety,
Læs mere